A basic review on estrogen receptor signaling pathways in breast cancer

L Clusan, F Ferrière, G Flouriot, F Pakdel - International journal of …, 2023 - mdpi.com
Breast cancer is the most common cancer and the deadliest among women worldwide.
Estrogen signaling is closely associated with hormone-dependent breast cancer (estrogen …

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

LA Huppert, O Gumusay, D Idossa… - CA: a cancer journal for …, 2023 - Wiley Online Library
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Advances in systemic therapies for triple negative breast cancer

RA Leon-Ferre, MP Goetz - Bmj, 2023 - bmj.com
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Annual report to the nation on the status of cancer, part 1: national cancer statistics

F Islami, EM Ward, H Sung, KA Cronin… - JNCI: Journal of the …, 2021 - academic.oup.com
Abstract Background The American Cancer Society, Centers for Disease Control and
Prevention, National Cancer Institute, and North American Association of Central Cancer …